One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Therapeutics ➤ Pruritus Therapeutics Market
Pruritus Therapeutics Market
Pruritus Therapeutics Market
Published date: Oct 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Therapeutics ➤ Pruritus Therapeutics Market

Pruritus Therapeutics Market By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, and Others), By Product (Corticosteroids, Antihistamines, Immunosuppressant, Calcineurin Inhibitors, Local Anesthetics, Counterirritants, and Others), By Distribution Channel (Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: Oct 2024
  • Report ID: 130646
  • Number of Pages: 368
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Disease Type Analysis
    • Product Analysis
    • Distribution Channel Analysis
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunities
    • Impact of Macroeconomic / Geopolitical Factors
    • Trends
    • Regional Analysis
    • Key Players Analysis
    • Recent Developments
    • Report Scope

    Report Overview

    The Pruritus Therapeutics Market size is expected to be worth around US$ 13.7 billion by 2033 from US$ 8.9 billion in 2023, growing at a CAGR of 4.4% during the forecast period 2024 to 2033.

    Pruritus Therapeutics Market Size

    Increasing awareness of the impact of pruritus on quality of life drives significant growth in the pruritus therapeutics market, particularly for conditions such as atopic dermatitis and chronic liver diseases. The prevalence of pruritus is notably high among various populations, with the National Eczema Association reporting that approximately 9.6 million children in the United States under 18 suffer from atopic dermatitis, one-third of whom experience moderate to severe symptoms.

    As healthcare providers seek effective treatment options, recent innovations in therapeutic agents have expanded available solutions for managing this challenging symptom. In July 2021, Albireo Pharma, Inc. introduced Bylvay, an FDA-approved medication designed specifically to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC). This launch highlights a growing trend toward developing targeted therapies that address the underlying causes of pruritus rather than merely alleviating symptoms.

    Additionally, the rising focus on personalized medicine opens new opportunities for customized treatment plans tailored to individual patient needs. Advances in formulation technologies and delivery systems further enhance drug efficacy and patient adherence, paving the way for improved outcomes. As more pharmaceutical companies invest in research and development within this niche market, the pruritus therapeutics landscape will likely continue to evolve, offering new hope to those affected by chronic itching.

    Key Takeaways

    • In 2023, the market for Pruritus Therapeutics generated a revenue of US$ 8.9 billion, with a CAGR of 4.4%, and is expected to reach US$ 13.7 billion by the year 2033.
    • The disease type segment is divided into atopic dermatitis, allergic contact dermatitis, urticaria, and others, with atopic dermatitis taking the lead in 2023 with a market share of 52.4%.
    • Considering product, the market is divided into corticosteroids, antihistamines, immunosuppressant, calcineurin inhibitors, local anesthetics, counterirritants, and others. Among these, corticosteroids held a significant share of 45.8%.
    • Furthermore, concerning the distribution channel segment, the market is segregated into hospital pharmacies, online providers and drug stores & retail pharmacies. The hospital pharmacies sector stands out as the dominant player, holding the largest revenue share of 59.8% in the Pruritus Therapeutics market.
    • North America led the market by securing a market share of 38.9% in 2023.

    Disease Type Analysis

    The atopic dermatitis segment led in 2023, claiming a market share of 52.4% owing to the rising prevalence of this chronic skin condition. Increasing awareness of atopic dermatitis among both healthcare providers and patients is likely to drive demand for effective treatment options. The growing understanding of the underlying causes of this disease, including genetic and environmental factors, is anticipated to enhance the development of targeted therapies.

    Additionally, the introduction of innovative biologics and topical treatments specifically designed for atopic dermatitis is projected to improve patient outcomes and compliance. The expanding patient population, particularly among children and young adults, will further contribute to the growth of this segment. As more individuals seek effective management strategies for this condition, the atopic dermatitis segment is likely to solidify its position in the overall therapeutic landscape.

    Product Analysis

    The corticosteroids held a significant share of 45.8% as these agents remain the first line of treatment for various skin conditions, including eczema and dermatitis. The effectiveness of corticosteroids in reducing inflammation and itching makes them a popular choice among healthcare providers, driving their continued usage. As the prevalence of skin disorders rises, the demand for corticosteroid formulations is expected to increase correspondingly.

    Furthermore, advancements in drug delivery systems, such as improved topical formulations and combination therapies, are likely to enhance the efficacy and safety profiles of corticosteroids. The ongoing emphasis on developing more potent yet safer corticosteroid options is anticipated to attract more patients seeking relief from pruritic conditions. As a result, the corticosteroids segment is estimated to maintain a significant share within the overall therapeutics market for itch relief.

    Distribution Channel Analysis

    The hospital pharmacies segment had a tremendous growth rate, with a revenue share of 59.8% as healthcare institutions increasingly focus on providing comprehensive medication management. The rising prevalence of skin disorders requiring prescription medications drives the demand for hospital pharmacies to stock a wide range of effective treatments.

    Moreover, the convenience and accessibility of medications offered through hospital pharmacies are likely to enhance patient adherence to prescribed therapies. The integration of pharmacy services within hospitals facilitates better patient care, as pharmacists can provide personalized medication counseling and monitoring.

    Additionally, ongoing collaborations between healthcare providers and pharmacists are anticipated to improve treatment outcomes, further solidifying the role of hospital pharmacies in managing pruritus. As the healthcare landscape evolves, the importance of hospital pharmacies in the distribution of effective pruritus therapeutics is projected to increase, reflecting broader trends in patient-centered care.

    Pruritus Therapeutics Market Share

    Key Market Segments

    By Disease Type

    • Atopic Dermatitis
    • Allergic Contact Dermatitis
    • Urticaria
    • Others

    By Product

    • Corticosteroids
    • Antihistamines
    • Immunosuppressant
    • Calcineurin Inhibitors
    • Local Anesthetics
    • Counterirritants
    • Others

    By Distribution Channel

    • Hospital Pharmacies
    • Online Providers
    • Drug Stores & Retail Pharmacies

    Drivers

    Growing Prevalence of Skin Disorders

    Increasing prevalence of skin disorders significantly drives the pruritus therapeutics market. Conditions such as eczema and atopic dermatitis affect millions worldwide, leading to a high demand for effective treatments. According to the Life (Basel) Journal, a controlled study conducted in 2021 found that the prevalence rate of eczema among Swedish children was 34%.

    Given that itching often accompanies these skin diseases, the burden associated with eczema and atopic dermatitis remains substantial. As awareness of these conditions grows and more patients seek relief from chronic itch, the demand for effective pruritic drugs is expected to increase. Healthcare providers and pharmaceutical companies are likely to focus on developing innovative therapeutic options to meet the needs of affected individuals, further driving market growth.

    Restraints

    Lack of Standardized Treatment Protocols

    High levels of lack of standardized treatment protocols restrain the growth of the pruritus therapeutics market. The absence of universally accepted guidelines for managing itch complicates treatment strategies, leading to inconsistencies in care. Healthcare providers may struggle to determine the most effective therapies for patients suffering from pruritus due to variations in treatment approaches.

    This lack of uniformity could impede the adoption of new therapies, as providers may remain hesitant to prescribe untested or less familiar treatments. Furthermore, patients may experience delayed relief or inadequate treatment options, limiting overall market potential. As a result, this restraint is expected to hinder the market’s expansion, particularly in regions where healthcare practices vary widely.

    Opportunities

    Increase in Clinical Trials Presents Opportunities

    Rising number of clinical trials creates significant opportunities for the pruritus therapeutics market. Ongoing research efforts to develop new treatments for chronic itch are expanding rapidly, as pharmaceutical companies invest in innovative solutions. For example, a phase 3 trial conducted by Regeneron Pharmaceuticals, Inc. and Sanofi demonstrated that their drug, Dupixent, had a significant impact on itch within just 12 weeks.

    As more clinical trials yield positive results, the introduction of effective new therapies is likely to enhance patient care and increase demand. This surge in research activity is anticipated to lead to a broader range of therapeutic options, thereby driving growth in the pruritus therapeutics market as stakeholders work to address unmet needs and improve treatment outcomes for patients suffering from itch-related conditions.

    Impact of Macroeconomic / Geopolitical Factors

    Macroeconomic and geopolitical factors significantly influence the market for itch relief treatments. Economic fluctuations can lead to reduced healthcare spending, which may limit the availability of new therapies and negatively impact patient access to essential medications. Rising inflation increases production costs, potentially leading to higher prices for consumers and reduced affordability of treatments. Geopolitical tensions and trade disputes can disrupt the supply chain, affecting the timely delivery of critical ingredients and formulations.

    However, growing awareness of dermatological conditions and the increasing prevalence of chronic diseases create substantial demand for effective therapies. Moreover, government initiatives to improve healthcare access and funding for research promote innovation in treatment options. Ultimately, despite challenges, the ongoing commitment to addressing patients’ needs and enhancing treatment accessibility presents a positive outlook for the industry.

    Trends

    Impact of Approval of New Treatments on the Pruritus Therapeutics Market

    Increasing approvals of new treatments are projected to significantly drive growth in the market for itch relief therapies. Regulatory agencies are streamlining the approval processes, allowing innovative solutions to reach patients more quickly. The introduction of novel therapies offers hope for individuals suffering from various forms of pruritus, enhancing the treatment landscape.

    For example, in August 2023, the U.S. Food and Drug Administration (FDA) authorized VeopozTM for the treatment of adult and pediatric patients aged one year and older with CHAPLE disease, as reported by Regeneron Pharmaceuticals, Inc. Veopoz represents the first and only treatment specifically recommended for this condition. This approval addressed prior inspection concerns regarding the aflibercept 8 mg Biologics License Application (BLA).

    The FDA is likely to take further action on the aflibercept 8 mg BLA in the coming weeks, paving the way for additional treatment options. As new therapies continue to gain approval, the market is expected to expand, offering patients a wider range of effective solutions for managing their conditions.

    Regional Analysis

    North America is leading the Pruritus Therapeutics Market

    North America dominated the market with the highest revenue share of 38.9% owing to several critical factors that highlight the increasing prevalence of skin-related disorders. The rising incidence of chronic skin conditions, such as eczema and psoriasis, has heightened the demand for effective therapeutic options to alleviate itching. Increased awareness of the psychological impact of chronic itching has also prompted healthcare providers to prioritize the treatment of pruritus.

    Additionally, advancements in drug development have led to the introduction of innovative therapies specifically targeting chronic spontaneous urticaria (CSU), a severe and unpredictable skin condition. For instance, in January 2021, Novartis announced that the U.S. Food and Drug Administration granted breakthrough therapy designation for a treatment addressing CSU, reflecting the urgent need for effective solutions in this area.

    Moreover, growing research on the underlying mechanisms of pruritus has facilitated the development of targeted therapies, further driving market growth. Overall, these dynamics have fostered a robust environment for pruritus therapeutics in North America.

    The Asia Pacific region is expected to experience the highest CAGR during the forecast period

    In the Asia Pacific region, the pruritus therapeutics market is expected to witness substantial growth during the forecast period. The rising prevalence of dermatological disorders, coupled with an increasing population, is anticipated to drive demand for effective treatment options. Rapid urbanization and changing lifestyles are likely to contribute to higher incidences of allergic reactions and skin irritations, further boosting the market.

    Additionally, healthcare systems across the region are projected to enhance their focus on dermatological care, leading to improved access to innovative therapeutics. The growing awareness of the importance of addressing chronic itching, along with increased investments in research and development, is likely to facilitate the introduction of novel therapies.

    Furthermore, the expansion of healthcare infrastructure and the rising middle class are expected to enhance patient access to effective treatment solutions. As these trends continue to evolve, the pruritus therapeutics market in the Asia Pacific region is anticipated to flourish, driven by both rising demand and advancements in medical science.

    Pruritus Therapeutics Market Regions

    Key Regions and Countries

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Russia
      • Netherland
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Australia
      • New Zealand
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of MEA

    Key Players Analysis

    The major players in the Pruritus Therapeutics market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the pruritus market drive growth by focusing on innovative treatment options and enhancing patient accessibility. They invest heavily in research and development to create novel therapies, including biologics and topical agents that target underlying causes of itching.

    Establishing collaborations with dermatology clinics and healthcare providers facilitates broader distribution and helps to raise awareness about available treatments. Companies actively engage in mergers and acquisitions to diversify their product portfolios and strengthen their market position. Additionally, they focus on expanding into emerging markets, adapting their strategies to meet the unique healthcare needs and regulatory environments of these regions.

    Top Key Players in the Pruritus Therapeutics Market

    • Teva Pharmaceuticals
    • Sanofi
    • Pfizer Inc.
    • Novartis AG
    • Mylan NV
    • Ipsen
    • GlaxoSmithKline, Plc.
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Actavis Plc

    Recent Developments

    • In June 2023: Ipsen announced that Bylvay received approval from the United States Food and Drug Administration (FDA) for treating cholestatic pruritus in patients with Alagille syndrome starting at 12 months of age. Bylvay, an ileal bile acid transport inhibitor (IBATi), acts locally in the small intestine with minimal systemic exposure. Previously, in 2021, Bylvay had been authorized as the first medication therapy option for cholestatic pruritus caused by progressive familial intrahepatic cholestasis (PFIC) in Europe and for treating PFIC in the United States. The immediate availability of Bylvay for eligible ALGS patients signifies a significant advancement in treatment options, which is likely to drive growth in the pruritus therapeutics market by addressing unmet medical needs.
    • In 2022: Pfizer Inc. launched CIBINQO (abrocitinib), an oral treatment specifically designed for adults with atopic dermatitis. The introduction of this innovative therapy enhances the existing treatment landscape for atopic dermatitis, a condition often associated with pruritus. The availability of effective oral medications is expected to attract more patients seeking relief from symptoms, thereby contributing to the expansion of the pruritus therapeutics market.

    Report Scope

    Report Features Description
    Market Value (2023) US$ 8.9 billion
    Forecast Revenue (2033) US$ 13.7 billion
    CAGR (2024-2033) 4.4%
    Base Year for Estimation 2023
    Historic Period 2018-2022
    Forecast Period 2024-2033
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, and Others), By Product (Corticosteroids, Antihistamines, Immunosuppressant, Calcineurin Inhibitors, Local Anesthetics, Counterirritants, and Others), By Distribution Channel (Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies)
    Regional Analysis North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, Australia, New Zealand, Singapore, Thailand, Vietnam, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of MEA
    Competitive Landscape Teva Pharmaceuticals, Sanofi, Pfizer Inc., Novartis AG, Mylan NV, Ipsen, GlaxoSmithKline, Plc., Bristol-Myers Squibb, Astellas Pharma, and Actavis Plc.
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
    Pruritus Therapeutics Market
    Pruritus Therapeutics Market
    Published date: Oct 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Teva Pharmaceuticals
    • Sanofi Company Profile
    • Pfizer Inc Company Profile
    • Novartis AG Company Profile
    • Mylan NV
    • Ipsen
    • GlaxoSmithKline, Plc.
    • Bristol-Myers Squibb
    • Astellas Pharma, Inc Company Profile
    • Actavis Plc
  • settingsSettings

Related Reports

  • Digital Therapeutics Market
  • Acute Ischemic Stroke Therapeutics Market
  • Alzheimer’s disease therapeutics Market
  • Peptide Therapeutics Market
  • Leukemia Therapeutics Market
  • Gout Therapeutics Market
  • Cystic-Fibrosis Therapeutics Market
  • Aquaculture Therapeutics Market
  • Lung Disease Therapeutics Market
  • Allergy Diagnostics and Therapeutics Market
  • Stroke Diagnostics And Therapeutics Market
  • Infectious Disease Therapeutics Market

Our Clients

  • Our Clients
Inquiry Before Buying

Pruritus Therapeutics Market
  • 130646
  • Oct 2024
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.